In "Are Prescription Opioids Driving the Opioid Crisis? Assumptions vs Facts," Mark Rose presents a summary of the argument that the pendulum has swung too far from liberal to restrictive opioid policies. That argument states that we have misinterpreted the evidence and that patients are being harmed by being deprived of the most effective treatment for their chronic pain, long-term opioid therapy. He covers many issues in his essay. I will be only able to respond to a few of the most important.
Effectiveness of Long-term Opioid Therapy
Let me begin with the first sentence of the article because it is characteristic of the problems with the article as a whole: "Opioid analgesics remain the most effective drug class for controlling severe pain, but carry potential for adverse effects, misuse, and overdose." This sentence shifts from talking about the well-documented benefits of opioids for severe acute pain to talking about the well-documented harms of opioids for chronic pain, but the shift from acute to chronic pain is ignored or concealed. It is not at all clear that opioids are the most effective drug class for controlling severe chronic pain. The lack of evidence for this has been thoroughly reviewed by the Agency for Health Care Research and Quality (AHRQ) and the National Institutes of Health (NIH) [1] . Patients with the most severe chronic pain usually have substance use and mental health comorbidities that make them poor candidates for long-term opioid therapy [2, 3] . These patients have been excluded from controlled trials of opioids, but are the most likely to receive long-term and high-dose opioid therapy in clinical practice [4] . They have high rates of opioid adverse events such as misuse, abuse, addiction, overdose, and death [5,6]. It was not just the "media [who] began shifting the public perception of opioid analgesics," but the scientific community.
Later in his first paragraph, Mr. Rose refers to "patients whose quality of life and function benefit from opioid analgesia." Over the past three decades, we have seen a dramatic expansion and then a dramatic contraction in the presumed size of this opioid-responsive group. In 1986, Portenoy and Foley suggested that "opioid maintenance therapy can be a safe, salutary and more humane alternative to the options of surgery or no treatment in those patients with intractable nonmalignant pain and no history of drug abuse" [7] . By 1996, the American Academy of Pain Medicine and the American Pain Society issued a consensus statement on the "The Use of Opioids for the Treatment of Chronic Pain" that urged consideration of opioids as "an essential part of a pain management plan" in chronic pain, as in acute pain and cancer pain [8] . A letter to the New England Journal of Medicine describing chart reviews of inpatients treated with opioids titled "Addiction Rare in Patients Treated with Narcotics" [9] was cited over 600 times in the scientific literature and many more times in opioid marketing materials as evidence that outpatients treated for pain with opioids have a low risk of addiction [10] . Many states removed restrictions on long-term opioid therapy in "intractable pain acts" [11] . These steps, among many others, expanded the pool of patients eligible for long-term opioid therapy far beyond what it had been previously. This expansion of the opioid recipient pool led to a quadrupling of opioid prescriptions, overdose deaths, and substance use admissions between 2000 and 2010 [12] .
Until recently, the Food and Drug Administration (FDA), AHRQ, and NIH were willing to allow extrapolation from the effectiveness of opioid therapy for chronic pain in 12-week randomized controlled trials to claims of effectiveness over months and years in clinical practice. After an evidence review from the AHRQ, a consensus conference at the NIH, and a summary article in Annals of Internal Medicine, scientific consensus has shifted to consider the evidence for the effectiveness of long-term opioid therapy to be inadequate [1] . Why the glass of opioid evidence shifted from being seen as half-full to half-empty is not entirely clear, but reasons to doubt the broad effectiveness of opioid therapy have been available prior to this recent shift. Population-based studies of patients receiving long-term opioid therapy have consistently shown high levels of pain, distress, and disability in these populations [13] [14] [15] [16] [17] . Of course, it can be argued that these patients might be even worse without opioid therapy, but we have no solid evidence of this. The available data suggest that long-term opioid therapy does not have a significant positive effect on the health status of the broad population of patients with chronic pain. Hence, it is not at all clear what is "appropriate access to opioid analgesics for patients with chronic pain."
Randomized trials of long-term opioid therapy for chronic pain are rare. However, Krebs and colleagues [18] presented the results of their Strategies for Prescribing Analgesics Comparative Effectiveness (SPACE) at the Society for General Internal Medicine V C 2018 American Academy of Pain Medicine. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com (SGIM) last year. This trial randomized 240 veterans with moderate to severe chronic back pain or osteoarthritis pain of the hip or knee to 12 months of opioid therapy (mostly morphine and hydrocodone) or nonopioid therapy (mostly acetaminophen and naproxen). Pain intensity at trial completion was 4/10 in the opioid group and 3.5 in the nonopioid group (P ¼ 0.034). Yes, it was worse in the opioid group. The percentage of patients with clinically significant improvement in pain was higher in the nonopioid group (54%) than in the opioid group (41%). Opioid therapy also produced more medicationrelated adverse symptoms. Pain interference with function was the same in both groups.
Evidence from opioid discontinuation studies also casts doubt on the effectiveness of long-term opioid therapy. We recently published a pilot randomized trial of opioid taper support [19] . Those patients randomized to taper support achieved lower opioid doses, and they had no worse pain and less pain interference than the control group. A recent systematic review of opioid taper studies suggests that several types of interventions may be effective to reduce or discontinue long-term opioid therapy, and furthermore, that pain, function, and quality of life may improve with opioid dose reduction [20] . This trial and this systematic review suggest that opioid policy should not be framed as a choice between pain control and opioid risk because it is possible to improve pain control while lowering opioid doses.
Consequences of Unrelieved Chronic Pain
Less pain is better than more pain, all other things being equal. This statement is not controversial, but it is important not to omit the last phrase. We must include the price of lessening pain into the calculation. Mr. Rose discusses a set of consequences of uncontrolled chronic pain. He first discusses depression and suicide. Many of us have hoped that treatment of chronic pain with opioids would lessen its association with depression and suicide. Unfortunately, this does not appear to be the case. Scherrer and colleagues have used propensity scores and inverse probability of treatment weighting (IPTW) to correct for the increased likelihood that depressed patients will be prescribed opioids as they have investigated whether opioid prescription increases depression. Using data from large veteran and civilian samples, they have shown that long-term opioid therapy increases the risk for incident, recurrent, and treatment-resistant depression [21] [22] [23] . Patients who develop depression after long-term opioid use tend to have more depression symptoms, more PTSD and other anxiety disorders, and more opioid abuse and dependence than those who developed depression without opioid use [24] . An Australian study found that patients who developed depression after receiving opioids tended to have lower pain self-efficacy, poorer social support, younger onset of opioid use, and more difficulties and concerns with opioid use [25] .
Mr. Rose also mentions suicide as a consequence of chronic unrelieved pain. There is indeed some evidence of suicidal ideation and suicidal self-directed violence after clinician-initiated opioid discontinuation among veteran long-term opioid users, especially for high-risk patients with post-traumatic stress disorder or psychosis [26] . Abrupt withdrawal or unsupported taper of long-term high-dose opioid therapy can produce distressing and painful withdrawal. However, we recently published a study using data on the entire US population from the Centers for Disease Control and Prevention's (CDC's) WONDER online database showing that opioid involvement in suicides has doubled between 1999 and 2014. This effect was most marked in individuals aged 45 to 64 years, who have also shown the highest mortality from unintentional overdose with prescription opioids [27] . This is the same group noted to have uniquely escalating all-cause mortality by Case and Deaton [28] . It is possible that opioid exposure increases suicide risk and that abrupt discontinuation of that therapy further increases suicide risk. But there is no evidence that more liberal prescribing of opioids for chronic pain would lower suicide risk.
Mr. Rose mentions the neurotoxicity of undercontrolled pain. There is no doubt that uncontrolled pain is bad. However, this must be balanced against the neurotoxicity of long-term exposure to exogenous opioids. Jane Ballantyne and I have recently reviewed the functions of the endogenous opioid system and the effects of exogenous opioids on this system [29] . The endogenous opioid system is closely integrated with the dopamine system, and both systems mediate many forms of reward beyond pain relief. This is why, for example, the opioid antagonist naltrexone is used to treat alcoholism [30] . This endogenous opioid system has evolved to modulate the experiences of both physical pain and social pain, so it is not possible to aim opioid medications at physical pain only. When we use opioid medications chronically and continuously, we compromise normal healthy goal-directed behaviors, socialization, and emotional function. Patients tapered off long-term opioid therapy often report that the change they notice the most with opioid taper is no longer being a "zombie" with no emotional responses or social connections to others.
Are Prescription Opioids Responsible for the Epidemic of Overdose Fatalities?
Mr. Rose begins his section on "Opioid Analgesic Prescribing Rates" with the following: "Misperception: Continued increases in opioid analgesic prescribing fuel the opioid epidemic. Fact: Hydrocodone, oxycodone, and overall opioid prescribing have been in multiyear decline beginning in 2012 through early 2017." It is indeed true that opioid prescribing peaked nationally around 2012 [31] . This appears to be the primary reason that prescription opioid deaths have also peaked. This has been well documented in Washington State. In fact, guidelines that set limits on opioid daily doses (such as Commentary the controversial 2007 Washington guidelines), are the only policy that has been demonstrated to reduce prescription opioid mortality [32] . Despite the popularity of "universal precautions" and risk stratification in opioid treatment guidelines, these have never been shown to decrease overdoses or mortality. A recent study of the mortality effects of guideline-concordant opioid care showed that including psychotherapeutic co-interventions and rehabilitative therapies decreased mortality in veterans receiving long-term opioid therapy, but primary care visits and urine drug screens did not [33] . The bulk of available evidence therefore suggests that it is not possible to do safer opioid prescribing without doing less opioid prescribing. This important conclusion is absent from Mr. Rose's essay.
Under the heading "Opioid Analgesics as Causative Agent in Overdose Fatalities," Mr. Rose lists the following statements: "Misperception: Fatal ODs reflect the inherent lethality of opioid analgesics. Fact: Opioid analgesics are infrequently the sole cause of fatal overdose." Both statements are true. Most opioid overdose fatalities are multidrug overdoses including sedatives, or alcohol or other illicit drugs. The initial CDC study on opioid overdoses in West Virginia made it look like these deaths were caused by bad patient behavior, not bad drugs. Among those who died, most of the men were using diverted drugs and most of the women were doctor shopping [34] . But subsequent studies have shown a clear relationship between prescribed opioid dose and overdose risk, highlighting the inherent dangers of opioids [35, 36] .
Mr. Rose correctly argues that illicit opioids are now responsible for most opioid-related mortality. But he wants to make a stronger argument than this, as indicated by the following statements under the heading "Prescription Opioid Analgesic Abuse and Heroin Initiation": "Misperception: Prescription opioid analgesics are the gateway to heroin. Fact: Progression from prescription opioid abuse to heroin initiation is infrequent." Both of these statements are true. Prescription opioids are now indeed the gateway to heroin, though this has not always been true. In the 1960s, more than 80% of heroin users reported that their first opioid was heroin, but in the 2000s, 75% of users started opioid use with prescription opioids [37] . The widespread prescription of Oxycontin and other extended-release opioids in the 1990s and 2000s created a population of opioiddependent people that had not existed before (especially in rural America) who were then targeted by new Mexican heroin dealers [38] . Multiple studies confirm that most current heroin users used prescription opioids nonmedically first, even though the transition to heroin occurs at a low rate. It is also important to note that "there is no consistent evidence of an association between the implementation of policies related to prescription opioids and increases in the rates of heroin use or deaths, although the data are relatively sparse" [39] .
There have been longstanding questions about the role in the opioid epidemic of legitimate opioid prescriptions to patients with chronic pain. A recent study by Olfson et al. [40] has shed some light on this issue. These authors identified more than 13,000 Medicaid patients who had opioid-related deaths. Most of these (61.5%) had received a diagnosis of a chronic noncancer pain condition in the last year of life. Those with these diagnoses were more likely to have filled prescriptions for opioids and prescriptions for benzodiazepines in the last 30 days of life. They were also more likely to have received diagnoses of drug use, anxiety, and depression disorders. This study thus suggests that opioid prescription to Medicaid patients with chronic pain is contributing significantly to opioid-related mortality.
Conclusion
Where are we to go from here? The opioid epidemic has precipitated a crisis in pain medicine. We are only beginning to accept that one of the most potent and reliable pharmacological tools for pain control, opioid medications, cannot be at the center of our efforts to combat chronic pain. Science of many different types (e.g., pharmacology, evolutionary biology, pharmacoepidemiology, addiction medicine) is forcing this conclusion on us. Our deep-rooted desire to help the suffering patient in front of us drives us to write opioid prescriptions. And indeed, these prescriptions often make patients feel better soon. Unfortunately, these prescriptions usually make these patients worse over the following months to years in diverse and unanticipated ways. And we are seeing the downstream effects of our liberal prescribing ripple through the population of young adults using illicit opioids. Hence, we must do less opioid prescribing, as recommended in the CDC guidelines [41] .
How many patients who choose to stay on long-term opioid therapy are actually better off on this therapy compared with alternative therapies? We do not have controlled evidence about this. There are undoubtedly a few. But there are-also undoubtedly-not many. Regrettably, we cannot simply ask these patients about net benefit from long-term opioid therapy because of the tolerance and dependence produced by opioid medications. Patients tend to overvalue the relief they experience when initiating or dose-escalating opioids and overvalue the distress they experience when abruptly discontinuing opioids. This leads them to undervalue the persistent pain, distress, and disability they experience in the midst of long-term opioid therapy. If you ask carefully, the vast majority of patients on longterm opioid therapy report ambivalence about this therapy. They tell us that they would love to taper or stop opioids if there were any viable alternative. But they don't want to be abandoned to their pain.
We must do better for our patients. We sold them longterm opioid therapy as safe and effective. But it is probably neither. The opioid epidemic has produced more deaths in the United States than the AIDS epidemic.
We cannot go on prescribing opioids as we have for the past two decades. But in this crisis lies an opportunity to re-invent ourselves for the postopioid era in chronic pain care. 
